In vitro studies confirm that linagliptin suppresses the proliferation of several tumor cell lines, including colorectal cancer HCT116, breast cancer MCF-7, and liver cancer HepG2, via mechanisms that involve cell cycle arrest and apoptosis induction [96]
Surgery confers multiple downstream benefits: Lower rates of obesity-related comorbidities (like hypertension, hyperlipidemia, sleep apnea) compared to GLP-1 therapy at follow-up JAMA Network Reduced health care utilization: fewer inpatient stays, outpatient visits, and ED visits per patient per month post-surgery compared to GLP-1 therapy
Sometimes they were trauma problems
4,5,6 Since 2008, the Food and Drug Administration (FDA) and European Medicines Agency have required that new T2D pharmacotherapies undergo rigorous cardiovascular safety clinical trials using hard cardiovascular endpoints and more stringent statistical review
Stratified analyses in higher-risk groupssuch as older adults, individuals with sarcopenic obesity, or those with elevated inflammatory burdenmay further determine whether adaptive thresholds differ across metabolic contexts
